<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidermal nevus and epidermal nevus syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidermal nevus and epidermal nevus syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidermal nevus and epidermal nevus syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Teresa S Wright, MD, FAAD, FAAP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H512657202"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Epidermal nevi are benign, hamartomatous growths of the skin that are present at birth or develop in early childhood. They may be composed of a variety of epidermal cells and structures, including keratinocytes, sebaceous glands, hair follicles, apocrine and eccrine glands, and smooth muscle cells, and are thought to represent a form of cutaneous mosaicism [<a href="#rid1">1,2</a>]. Lesions with prominent adnexal components (eg, sebaceous, follicular, and/or apocrine) are sometimes referred to as "organoid," while lesions with primarily epidermal differentiation are known as "non-organoid" or "keratinocytic" nevi.</p><p>Keratinocytic epidermal nevi, also called linear epidermal nevi or linear verrucous epidermal nevi, are the most common form. They present as linear or whorled, skin-colored to brown plaques that tend to follow linear patterns on the skin known as "lines of Blaschko" (<a class="graphic graphic_figure graphicRef57219" href="/z/d/graphic/57219.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef64855 graphicRef86582 graphicRef89777" href="/z/d/graphic/64855.html" rel="external">picture 1A-C</a>).</p><p>This topic will review the pathogenesis, clinical presentation, and management of linear epidermal nevus. Nevus sebaceous is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13734.html" rel="external">"Nevus sebaceus and nevus sebaceus syndromes"</a>.)</p><p class="headingAnchor" id="H512657223"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Epidermal nevi occur in approximately 1 to 3 per 1000 live births; males and females tend to be equally affected [<a href="#rid2">2</a>].<sup> </sup>Most epidermal nevi occur sporadically as an isolated finding, but they also may occur in association with a variety of developmental abnormalities. Familial cases have been reported [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H512657244"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Epidermal nevi originate from pluripotential germinative cells in the basal layer of the embryonic epidermis. They are thought to represent forms of mosaicism, resulting from postzygotic mutations (or other genetic alteration) in embryonic cells destined to populate a particular area of the epidermis. Theoretically, mutations occurring very early in embryonic development give rise to more extensive epidermal nevi and may potentially affect additional organ systems [<a href="#rid5">5</a>].</p><p>Activating mutations in the fibroblast growth factor receptor 3 gene (<em>FGFR3</em>) and in the <em>PIK3CA</em> and <em>HRAS</em> oncogenes have been identified in keratinocytic nevi [<a href="#rid6">6-8</a>]. The epidermolytic variant of epidermal nevus harbors the same mutation in <em>KRT1 </em>or <em>KRT10</em> genes responsible for epidermolytic hyperkeratosis (EHK), a rare, autosomal dominant genodermatosis [<a href="#rid9">9,10</a>]. Patients with this type of epidermal nevus may have gonadal mosaicism and may transmit the mutation to their offspring [<a href="#rid11">11-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/97333.html" rel="external">"Keratinopathic ichthyoses", section on 'Epidermolytic ichthyosis'</a>.)</p><p class="headingAnchor" id="H512657251"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Histologically, epidermal nevi are characterized by hyperkeratosis, acanthosis, and papillomatosis (<a class="graphic graphic_picture graphicRef89244" href="/z/d/graphic/89244.html" rel="external">picture 2</a>) [<a href="#rid14">14</a>]. Some lesions may show the distinctive, church-spire pattern of acanthosis and hyperkeratosis that mimics acrokeratosis verruciformis, horn pseudocysts resembling seborrheic keratoses, or features of common warts [<a href="#rid15">15</a>].</p><p>Marked hyperkeratosis with lysis of epidermal cells above the basal layer is found in a histologic variant of epidermal nevus called "epidermolytic verrucous epidermal nevus." This variant carries the genetic mutation for epidermolytic hyperkeratosis (EHK), a rare, autosomal dominant genodermatosis caused by a mutation in <em>KRT1 </em>or <em>KRT10</em> genes, encoding keratin 1 and 10, respectively [<a href="#rid2">2</a>].</p><p>The inflammatory linear verrucous epidermal nevus (ILVEN) is a clinically and histologically distinct variant of the epidermal nevus that displays a chronic dermal inflammatory infiltrate, psoriasiform epidermal hyperplasia, and alternating bands of ortho- and parakeratosis [<a href="#rid16">16</a>].</p><p>Appendageal anomalies may be seen in early childhood and include immature hair follicles, sebaceous, eccrine, or apocrine glands.</p><p class="headingAnchor" id="H14356273"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H14356352"><span class="h2">Linear verrucous epidermal nevus</span><span class="headingEndMark"> — </span>Most epidermal nevi are present at birth or occur during the first year of life [<a href="#rid2">2</a>]. Occasionally, they may appear later in childhood or during adulthood (<a class="graphic graphic_picture graphicRef64855 graphicRef86582" href="/z/d/graphic/64855.html" rel="external">picture 1A-B</a>). Initially, they appear as subtle, linear patches and/or thin plaques consisting of closely set or coalescing, skin-colored or brown, verrucous papules. Over time, particularly around puberty, they tend to darken and thicken (<a class="graphic graphic_picture graphicRef89777" href="/z/d/graphic/89777.html" rel="external">picture 1C</a>).</p><p>The distribution and extent of epidermal nevi vary widely; they can be solitary, multiple, large, or small and usually are located on the trunk or extremities [<a href="#rid2">2</a>]. Rare cases involving the oral mucosa have been described [<a href="#rid17">17</a>]. Lesions tend to follow patterns of precursor cell migration and proliferation in the skin known as "lines of Blaschko" (<a class="graphic graphic_figure graphicRef57219" href="/z/d/graphic/57219.html" rel="external">figure 1</a>) and often show a sharp midline demarcation.</p><p>A verrucous epidermal nevus with extensive bilateral distribution is called "systematized epidermal nevus" (<a class="graphic graphic_picture graphicRef89783 graphicRef89779" href="/z/d/graphic/89783.html" rel="external">picture 3A-B</a>). A variant involving one-half of the body is termed "nevus unius lateris" (<a class="graphic graphic_picture graphicRef89782" href="/z/d/graphic/89782.html" rel="external">picture 4</a>). Typically, systematized epidermal nevi take on a transverse configuration on the trunk and a linear configuration on the limbs.</p><p>Linear epidermal nevi are usually asymptomatic. Pruritus and scaling are common in the inflammatory variant described below.</p><p class="headingAnchor" id="H4129220"><span class="h2">Inflammatory linear verrucous epidermal nevus</span><span class="headingEndMark"> — </span>Inflammatory linear verrucous epidermal nevus (ILVEN) is a rare variant of epidermal nevus. It typically presents in early childhood and is characterized by pruritic, erythematous, and hyperkeratotic papules that often coalesce into plaques (<a class="graphic graphic_picture graphicRef89763" href="/z/d/graphic/89763.html" rel="external">picture 5</a>) [<a href="#rid1">1</a>]. It is usually unilateral and most often located on the lower half of the body, with a linear distribution that follows the lines of Blaschko.</p><p class="headingAnchor" id="H269049"><span class="h2">Clinical course and complications</span><span class="headingEndMark"> — </span>The majority of epidermal nevi remain quiescent after adolescence. Flexural lesions may become macerated, superinfected, and foul smelling, causing discomfort and psychological problems. Rare cases of basal cell carcinoma and squamous cell carcinoma arising within epidermal nevi have been reported in older individuals [<a href="#rid18">18-23</a>].</p><p class="headingAnchor" id="H14356009"><span class="h1">EPIDERMAL NEVUS SYNDROME</span><span class="headingEndMark"> — </span>The term "epidermal nevus syndrome" has been used to describe the association of an epidermal nevus with other developmental anomalies, which most commonly involve the brain, eye, and musculoskeletal system [<a href="#rid1">1,2,24</a>]. Syndromes associated with linear epidermal nevi include [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Proteus syndrome, a rare complex disorder presenting with malformations and overgrowth of multiple tissues (<a class="graphic graphic_picture graphicRef89784" href="/z/d/graphic/89784.html" rel="external">picture 6</a>). (See  <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Proteus-like syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 2 (segmental) Cowden syndrome, a multisystem inherited disorder characterized by the presence of a specific keratinocytic nevus called linear Cowden nevus [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Cowden syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, an X-linked dominant, male-lethal phenotype caused by mutations in the <em>NSDHL</em> gene, encoding a 3-beta-hydroxysteroid dehydrogenase involved in cholesterol metabolism [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibroblast growth factor receptor 3 epidermal nevus (FGFR3) syndrome, characterized by the presence of a systematized epidermal nevus and brain defects, including cortical atrophy, subdural hygroma, and hypoplasia of the corpus callosum [<a href="#rid27">27</a>]. This syndrome is considered a mosaic manifestation of thanatophoric dysplasia, a lethal skeletal dysplasia. (See  <a class="medical medical_review" href="/z/d/html/14209.html" rel="external">"Approach to prenatal diagnosis of the lethal (life-limiting) skeletal dysplasias", section on 'Thanatophoric dysplasia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a rare disorder defined by the association of epidermal or melanocytic nevi, hypophosphatemic rickets, and elevated levels of circulating fibroblast growth factor-23 (FGF-23) [<a href="#rid28">28,29</a>]. It is caused by multilineage activating <em>RAS</em> mutations in skin and bone, resulting in elevated levels of circulating FGF-23 [<a href="#rid28">28</a>]. FGF-23 is a 30-kd phosphatonin normally secreted from osteocytes, which regulates both phosphate and vitamin-D homeostasis by modulating the expression of renal phosphate transporters and calcitriol-metabolizing enzymes [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H14356367"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>In most cases, the diagnosis of linear epidermal nevus is made clinically, based upon the finding of verrucous papules and plaques in a linear distribution along the lines of Blaschko (<a class="graphic graphic_picture graphicRef89777" href="/z/d/graphic/89777.html" rel="external">picture 1C</a>). If the diagnosis is in question, a skin biopsy may be necessary for histopathologic confirmation. (See <a class="local">'Histopathology'</a> above.)</p><p class="headingAnchor" id="H512657272"><span class="h2">Additional evaluation</span><span class="headingEndMark"> — </span>Children with small, isolated epidermal nevi and a normal physical exam usually do not require further work-up. However, the presence of large or extensive epidermal nevi should prompt evaluation for potential involvement of other organ systems. (See <a class="local">'Epidermal nevus syndrome'</a> above.)</p><p>A thorough prenatal, perinatal, neonatal, and developmental history should be obtained, and a careful physical examination should be performed. A neurologic exam is critical, as is examination of the eyes, especially the conjunctiva, sclerae, and extraocular eye movements [<a href="#rid1">1</a>]. Skeletal exam should include evaluation for kyphoscoliosis and gait assessment. Limb length and size should be measured to ascertain any asymmetry.</p><p>The choice of imaging studies should be individualized depending upon the nature of the suspected abnormalities and might include skull and chest radiographs, skeletal imaging, magnetic resonance imaging (MRI) of the head, and electroencephalogram (EEG).</p><p class="headingAnchor" id="H14356399"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of epidermal nevus includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen striatus</strong> – Lichen striatus is a rare, idiopathic papular eruption of childhood characterized by the sudden onset of flat-topped, skin-colored or hyperpigmented papules arranged in a linear configuration along the lines of Blaschko (<a class="graphic graphic_picture graphicRef89804 graphicRef89805" href="/z/d/graphic/89804.html" rel="external">picture 7A-B</a>) [<a href="#rid30">30,31</a>]. The eruption typically resolves spontaneously in a few months to four years. Histology reveals a lichenoid lymphocytic infiltrate with overlying acanthosis and dyskeratosis. (See  <a class="medical medical_review" href="/z/d/html/13731.html" rel="external">"Lichen striatus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linear psoriasis</strong> – Linear psoriasis is an exceedingly rare variant of psoriasis that may be difficult to differentiate from inflammatory linear verrucous epidermal nevus (ILVEN) both clinically and histologically [<a href="#rid32">32-35</a>]. Clinical features that distinguish linear psoriasis from ILVEN include family history of psoriasis, onset later in life, absence of verrucous lesions, involvement of other sites (eg, nails, scalp, palms, and soles), milder pruritus, and response to antipsoriatic treatments [<a href="#rid32">32</a>]. On histology, linear psoriasis shows hyperkeratosis, parakeratosis, absence of granular cell layer, elongation of rete ridges, suprapapillary thinning, and Munro microabscesses. ILVEN typically shows alternating orthokeratosis and parakeratosis and alternating presence and absence of granular cell layer. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linear porokeratosis</strong> – Linear porokeratosis is a rare form of porokeratosis that typically presents during infancy or early childhood with single or multiple plaques with hyperkeratotic rims on the limbs or trunk (<a class="graphic graphic_picture graphicRef73545 graphicRef50928" href="/z/d/graphic/73545.html" rel="external">picture 8A-B</a>). Histology reveals the characteristic cornoid lamella, a thin column of tightly packed parakeratotic cells within a keratin-filled epidermal invagination (<a class="graphic graphic_picture graphicRef61211 graphicRef67831 graphicRef66289" href="/z/d/graphic/61211.html" rel="external">picture 9A-C</a>). (See  <a class="medical medical_review" href="/z/d/html/13721.html" rel="external">"Porokeratosis", section on 'Linear porokeratosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linear Darier disease</strong> – Darier disease is a rare, autosomal dominant genodermatosis that usually appears during the teenage years as skin-colored or yellow-brown keratotic papules that involve the face, chest, and back and, less frequently, the flexural areas (<a class="graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188" href="/z/d/graphic/70000.html" rel="external">picture 10A-E</a>). Linear forms of Darier disease can be differentiated from linear epidermal nevi by the typical histopathologic finding of acantholytic dyskeratosis. (See  <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">"Darier disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incontinentia pigmenti </strong>– Incontinentia pigmenti is a rare, X-linked, male-lethal genodermatosis that presents in the neonatal period with linear papules and vesicles (<a class="graphic graphic_picture graphicRef58769" href="/z/d/graphic/58769.html" rel="external">picture 11</a>). Within weeks or months, the initial lesions progress to verrucous streaks (<a class="graphic graphic_picture graphicRef89806" href="/z/d/graphic/89806.html" rel="external">picture 12</a>) that may mimic a verrucous epidermal nevus. However, the verrucous lesions of incontinentia pigmenti gradually resolve, leaving hyperpigmented whorls and swirls along the Blaschko lines (<a class="graphic graphic_picture graphicRef89807" href="/z/d/graphic/89807.html" rel="external">picture 13</a>). (See  <a class="medical medical_review" href="/z/d/html/15513.html" rel="external">"Incontinentia pigmenti"</a>.)</p><p></p><p class="headingAnchor" id="H512657279"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of epidermal nevi is difficult. Full-thickness excision provides definitive treatment for small lesions, but may not be an option for large or extensive lesions, due to the risk of disfiguring scarring [<a href="#rid36">36</a>]. Multiple alternative surgical or destructive approaches have been reported, including shave excision, cryotherapy, deep chemical peels, and laser ablation [<a href="#rid37">37-42</a>]. However, their efficacy is uncertain due to the lack of randomized trials or large observational studies with long-term follow-up.</p><p>Superficial excision techniques, such as shave excision, curettage, or dermabrasion, tend to produce only temporary benefit and are associated with a high risk of recurrence. Cryotherapy may be an option for small lesions. In one study, 11 patients with epidermal nevi were treated with two to five sessions of cryotherapy with good cosmetic results [<a href="#rid41">41</a>]. No recurrence was observed in 10 of 11 patients after a follow-up of 26 to 42 months.</p><p>Laser therapy is used increasingly for the treatment of epidermal nevi; improvements in technology and better selection of modality are gradually overcoming problems such as hypertrophic scarring, pigmentary changes, and partial recurrence. Continuous wave and pulsed carbon dioxide (CO<sub>2</sub>) laser vaporization has been used with good results in patients with soft, flat epidermal nevi [<a href="#rid39">39</a>]. Erbium:yttrium aluminum garnet (Er:YAG) laser ablation may provide better cosmetic results than CO<sub>2</sub> laser with minimal or no scarring. In a series of 20 patients with verrucous epidermal nevi treated with Er:YAG laser, healing occurred within 10 days without scarring [<a href="#rid37">37</a>]. However, recurrence was reported in 5 of 20 patients in 3 to 12 months.</p><p>Topical therapies have a limited place in the treatment of epidermal nevi. There are isolated reports of successful treatment with topical retinoids, topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, topical corticosteroids, topical <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">calcipotriol</a>, and <a class="drug drug_general" data-topicid="138308" href="/z/d/drug information/138308.html" rel="external">topical sirolimus</a> [<a href="#rid43">43-45</a>].</p><p>Systemic retinoids, such as <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, also have been used in patients with systematized epidermal nevi [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1469525"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>Patients with the epidermolytic histologic variant of epidermal nevus may have gonadal mosaicism for the mutation responsible for epidermolytic hyperkeratosis (EHK) and are at risk of having a child with EHK. For these patients, referral for genetic testing and counseling may be warranted. (See  <a class="medical medical_review" href="/z/d/html/97333.html" rel="external">"Keratinopathic ichthyoses", section on 'Epidermolytic ichthyosis'</a>.)</p><p class="headingAnchor" id="H1468375"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Epidermal nevi are benign, hamartomatous growths of the skin; they may be composed of a variety of cells and structures and are thought to represent a form of cutaneous mosaicism. Keratinocytic epidermal nevi, also called linear epidermal nevi, are the most common form. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Most epidermal nevi are present at birth or occur during the first year of life. They appear as linear patches or plaques of closely set, skin-colored or brown, verrucous papules that typically follow the lines of Blaschko (<a class="graphic graphic_picture graphicRef89777 graphicRef64855 graphicRef86582" href="/z/d/graphic/89777.html" rel="external">picture 1A-C</a> and <a class="graphic graphic_figure graphicRef57219" href="/z/d/graphic/57219.html" rel="external">figure 1</a>). Inflammatory linear verrucous epidermal nevus (ILVEN) is a rare erythematous and pruritic variant (<a class="graphic graphic_picture graphicRef89763" href="/z/d/graphic/89763.html" rel="external">picture 5</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidermal nevus syndrome</strong> – The term "epidermal nevus syndrome" has been used to describe the association of an epidermal nevus with other developmental anomalies, which most commonly involve the brain and the musculoskeletal system. (See <a class="local">'Epidermal nevus syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of linear epidermal nevus is clinical, based upon the typical finding of verrucous papules and plaques in a linear distribution. A skin biopsy may be necessary for histopathologic confirmation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of epidermal nevi is difficult. Full-thickness excision provides definitive treatment for small lesions. Alternative therapies include shave excision, cryotherapy, and laser ablation. (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sugarman JL. Epidermal nevus syndromes. Semin Cutan Med Surg 2007; 26:221.</a></li><li><a class="nounderline abstract_t">Brandling-Bennett HA, Morel KD. Epidermal nevi. Pediatr Clin North Am 2010; 57:1177.</a></li><li><a class="nounderline abstract_t">Fearfield LA, Bunker CB. Familial naevus sebaceous of Jadassohn. Br J Dermatol 1998; 139:1119.</a></li><li><a class="nounderline abstract_t">Happle R, König A. Familial naevus sebaceus may be explained by paradominant transmission. Br J Dermatol 1999; 141:377.</a></li><li><a class="nounderline abstract_t">Hafner C, Toll A, Real FX. HRAS mutation mosaicism causing urothelial cancer and epidermal nevus. N Engl J Med 2011; 365:1940.</a></li><li><a class="nounderline abstract_t">Hafner C, López-Knowles E, Luis NM, et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A 2007; 104:13450.</a></li><li><a class="nounderline abstract_t">Hafner C, van Oers JM, Vogt T, et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006; 116:2201.</a></li><li><a class="nounderline abstract_t">Hafner C, Toll A, Gantner S, et al. Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet 2012; 49:249.</a></li><li><a class="nounderline abstract_t">Paller AS, Syder AJ, Chan YM, et al. Genetic and clinical mosaicism in a type of epidermal nevus. N Engl J Med 1994; 331:1408.</a></li><li><a class="nounderline abstract_t">Tsubota A, Akiyama M, Sakai K, et al. Keratin 1 gene mutation detected in epidermal nevus with epidermolytic hyperkeratosis. J Invest Dermatol 2007; 127:1371.</a></li><li><a class="nounderline abstract_t">Akhyani M, Kiavash K, Kamyab K. Bullous ichthyosiform erythroderma in a child born to a parent with systematized linear epidermolytic hyperkeratosis. Int J Dermatol 2009; 48:215.</a></li><li><a class="nounderline abstract_t">Chassaing N, Kanitakis J, Sportich S, et al. Generalized epidermolytic hyperkeratosis in two unrelated children from parents with localized linear form, and prenatal diagnosis. J Invest Dermatol 2006; 126:2715.</a></li><li><a class="nounderline abstract_t">Kono M, Suga Y, Akashi T, et al. A Child with Epidermolytic Ichthyosis from a Parent with Epidermolytic Nevus: Risk Evaluation of Transmission from Mosaic to Germline. J Invest Dermatol 2017; 137:2024.</a></li><li><a class="nounderline abstract_t">Su WP. Histopathologic varieties of epidermal nevus. A study of 160 cases. Am J Dermatopathol 1982; 4:161.</a></li><li><a class="nounderline abstract_t">Ersoy-Evans S, Sahin S, Mancini AJ, et al. The acanthosis nigricans form of epidermal nevus. J Am Acad Dermatol 2006; 55:696.</a></li><li><a class="nounderline abstract_t">Dupre A, Christol B. Inflammatory linear verrucose epidermal nevus. A pathologic study. Arch Dermatol 1977; 113:767.</a></li><li><a class="nounderline abstract_t">Tesi D, Ficarra G. Oral linear epidermal nevus: a review of the literature and report of two new cases. Head Neck Pathol 2010; 4:139.</a></li><li><a class="nounderline abstract_t">Hafner C, Klein A, Landthaler M, Vogt T. Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis. Dermatology 2009; 218:278.</a></li><li><a class="nounderline abstract_t">De D, Kanwar AJ, Radotra BD. Basal cell carcinoma developing in verrucous epidermal nevus. Indian J Dermatol Venereol Leprol 2007; 73:127.</a></li><li><a class="nounderline abstract_t">Ceylan C, Ozdemir F, Oztürk G, Akalin T. A case of basal cell carcinoma arising in epidermal nevus. Int J Dermatol 2002; 41:926.</a></li><li><a class="nounderline abstract_t">Masood Q, Narayan D. Squamous cell carcinoma in a linear epidermal nevus. J Plast Reconstr Aesthet Surg 2009; 62:693.</a></li><li><a class="nounderline abstract_t">Turk BG, Ertam I, Urkmez A, et al. Development of squamous cell carcinoma on an inflammatory linear verrucous epidermal nevus in the genital area. Cutis 2012; 89:273.</a></li><li><a class="nounderline abstract_t">Toya M, Endo Y, Fujisawa A, et al. A metastasizing squamous cell carcinoma arising in a solitary epidermal nevus. Case Rep Dermatol Med 2012; 2012:109632.</a></li><li><a class="nounderline abstract_t">Asch S, Sugarman JL. Epidermal nevus syndromes: New insights into whorls and swirls. Pediatr Dermatol 2018; 35:21.</a></li><li><a class="nounderline abstract_t">Happle R. The group of epidermal nevus syndromes Part I. Well defined phenotypes. J Am Acad Dermatol 2010; 63:1.</a></li><li><a class="nounderline abstract_t">König A, Happle R, Bornholdt D, et al. Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome. Am J Med Genet 2000; 90:339.</a></li><li><a class="nounderline abstract_t">García-Vargas A, Hafner C, Pérez-Rodríguez AG, et al. An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. Am J Med Genet A 2008; 146A:2275.</a></li><li><a class="nounderline abstract_t">Lim YH, Ovejero D, Derrick KM, et al. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy. J Am Acad Dermatol 2016; 75:420.</a></li><li><a class="nounderline abstract_t">Ovejero D, Lim YH, Boyce AM, et al. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporos Int 2016; 27:3615.</a></li><li><a class="nounderline abstract_t">Peramiquel L, Baselga E, Dalmau J, et al. Lichen striatus: clinical and epidemiological review of 23 cases. Eur J Pediatr 2006; 165:267.</a></li><li><a class="nounderline abstract_t">Hauber K, Rose C, Bröcker EB, Hamm H. Lichen striatus: clinical features and follow-up in 12 patients. Eur J Dermatol 2000; 10:536.</a></li><li><a class="nounderline abstract_t">Saraswat A, Sandhu K, Shukla R, Handa S. Unilateral linear psoriasis with palmoplantar, nail, and scalp involvement. Pediatr Dermatol 2004; 21:70.</a></li><li><a class="nounderline abstract_t">Akelma AZ, Cizmeci MN, Kanburoglu MK, Mete E. A diagnostic dilemma: inflammatory linear verrucous epidermal nevus versus linear psoriasis. J Pediatr 2013; 162:879.</a></li><li><a class="nounderline abstract_t">Chien P Jr, Rosenman K, Cheung W, et al. Linear psoriasis. Dermatol Online J 2009; 15:4.</a></li><li><a class="nounderline abstract_t">Happle R. Linear psoriasis and ILVEN: is lumping or splitting appropriate? Dermatology 2006; 212:101.</a></li><li><a class="nounderline abstract_t">Lee BJ, Mancini AJ, Renucci J, et al. Full-thickness surgical excision for the treatment of inflammatory linear verrucous epidermal nevus. Ann Plast Surg 2001; 47:285.</a></li><li><a class="nounderline abstract_t">Park JH, Hwang ES, Kim SN, Kye YC. Er:YAG laser treatment of verrucous epidermal nevi. Dermatol Surg 2004; 30:378.</a></li><li><a class="nounderline abstract_t">Thual N, Chevallier JM, Vuillamie M, et al. [CO2 laser therapy of verrucous epidermal nevus]. Ann Dermatol Venereol 2006; 133:131.</a></li><li><a class="nounderline abstract_t">Paradela S, Del Pozo J, Fernández-Jorge B, et al. Epidermal nevi treated by carbon dioxide laser vaporization: a series of 25 patients. J Dermatolog Treat 2007; 18:169.</a></li><li><a class="nounderline abstract_t">Toyozawa S, Yamamoto Y, Kaminaka C, et al. Successful treatment with trichloroacetic acid peeling for inflammatory linear verrucous epidermal nevus. J Dermatol 2010; 37:384.</a></li><li><a class="nounderline abstract_t">Panagiotopoulos A, Chasapi V, Nikolaou V, et al. Assessment of cryotherapy for the treatment of verrucous epidermal naevi. Acta Derm Venereol 2009; 89:292.</a></li><li><a class="nounderline abstract_t">Alkhalifah A, Fransen F, Le Duff F, et al. Laser treatment of epidermal nevi: A multicenter retrospective study with long-term follow-up. J Am Acad Dermatol 2020; 83:1606.</a></li><li><a class="nounderline abstract_t">Kim JJ, Chang MW, Shwayder T. Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus. J Am Acad Dermatol 2000; 43:129.</a></li><li><a class="nounderline abstract_t">Koh MJ, Lee JS, Chong WS. Systematized epidermal nevus with epidermolytic hyperkeratosis improving with topical calcipotriol/betametasone dipropionate combination ointment. Pediatr Dermatol 2013; 30:370.</a></li><li><a class="nounderline abstract_t">Zhou AG, Antaya RJ. Topical sirolimus therapy for nevus sebaceus and epidermal nevus: A case series. J Am Acad Dermatol 2022; 87:407.</a></li><li><a class="nounderline abstract_t">Herman AR, Scott RA. Systematized epidermal nevus treated with isotretinoin. J Drugs Dermatol 2002; 1:195.</a></li></ol></div><div id="topicVersionRevision">Topic 13728 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18395670" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidermal nevus syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888465" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidermal nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9990391" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Familial naevus sebaceous of Jadassohn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468835" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Familial naevus sebaceus may be explained by paradominant transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22087699" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : HRAS mutation mosaicism causing urothelial cancer and epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673550" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16841094" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22499344" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Keratinocytic epidermal nevi are associated with mosaic RAS mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526210" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genetic and clinical mosaicism in a type of epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255957" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Keratin 1 gene mutation detected in epidermal nevus with epidermolytic hyperkeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200214" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bullous ichthyosiform erythroderma in a child born to a parent with systematized linear epidermolytic hyperkeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990804" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Generalized epidermolytic hyperkeratosis in two unrelated children from parents with localized linear form, and prenatal diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28532675" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A Child with Epidermolytic Ichthyosis from a Parent with Epidermolytic Nevus: Risk Evaluation of Transmission from Mosaic to Germline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7048967" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Histopathologic varieties of epidermal nevus. A study of 160 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010754" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The acanthosis nigricans form of epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/869546" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inflammatory linear verrucose epidermal nevus. A pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20512640" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Oral linear epidermal nevus: a review of the literature and report of two new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19122450" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17456927" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Basal cell carcinoma developing in verrucous epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12492992" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A case of basal cell carcinoma arising in epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18514604" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Squamous cell carcinoma in a linear epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22838090" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Development of squamous cell carcinoma on an inflammatory linear verrucous epidermal nevus in the genital area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23259077" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A metastasizing squamous cell carcinoma arising in a solitary epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29044700" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Epidermal nevus syndromes: New insights into whorls and swirls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20542174" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The group of epidermal nevus syndromes Part I. Well defined phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710235" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18642369" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27444071" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27497815" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16411095" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lichen striatus: clinical and epidemiological review of 23 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11056425" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lichen striatus: clinical features and follow-up in 12 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871332" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Unilateral linear psoriasis with palmoplantar, nail, and scalp involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23149170" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A diagnostic dilemma: inflammatory linear verrucous epidermal nevus versus linear psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19891912" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Linear psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484813" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Linear psoriasis and ILVEN: is lumping or splitting appropriate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11562033" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Full-thickness surgical excision for the treatment of inflammatory linear verrucous epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15008864" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Er:YAG laser treatment of verrucous epidermal nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508596" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : [CO2 laser therapy of verrucous epidermal nevus].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538806" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Epidermal nevi treated by carbon dioxide laser vaporization: a series of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20507413" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Successful treatment with trichloroacetic acid peeling for inflammatory linear verrucous epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479129" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment of cryotherapy for the treatment of verrucous epidermal naevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31202870" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Laser treatment of epidermal nevi: A multicenter retrospective study with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10863239" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22938157" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Systematized epidermal nevus with epidermolytic hyperkeratosis improving with topical calcipotriol/betametasone dipropionate combination ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34428533" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Topical sirolimus therapy for nevus sebaceus and epidermal nevus: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847745" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Systematized epidermal nevus treated with isotretinoin.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
